Levy, R. at ASH

[Guest guest]

Dr. Levy is listed as a contributing author in the following abstracts at ASH

2008:

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and

Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and

Chronic Lymphocytic Leukemia (SLL/CLL)

http://ash.confex.com/ash/2008/webprogram/Paper5094.html

Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells

Correlates with Follicular Lymphoma Patient Clinical Outcomes

http://ash.confex.com/ash/2008/webprogram/Paper15232.html

T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma [in mice]

without the Need for Chemotherapy

http://ash.confex.com/ash/2008/webprogram/Paper2381.html

Combined Treatment with Short Synthetic Anti-Lymphoma Peptide and CpG ODN; A

Therapeutic Vaccine Which cures the A20 Lymphoma in Balb/C Mice

http://ash.confex.com/ash/2008/webprogram/Paper6420.html

Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees

http://ash.confex.com/ash/2008/webprogram/Paper11504.html

A CpG-Activated Whole-Cell Vaccine 'Boost' Enhances the Anti-Lymphoma Efficacy

of Immunotransplant

http://ash.confex.com/ash/2008/webprogram/Paper14822.html

Neither CD68+ Nor CD163+ Macrophages Are Associated with Decreased Survival in

Follicular Lymphoma

http://ash.confex.com/ash/2008/webprogram/Paper10808.html

Lymphoma-Expressed VEGF-a, VEGFR-1, VEGFR-2, and Microvessel Density Are Not

Predictive of Overall Survival in Follicular Lymphoma

http://ash.confex.com/ash/2008/webprogram/Paper13151.html

LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell

Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study

http://ash.confex.com/ash/2008/webprogram/Paper13376.html

All the best,

~ Karl